Physician profile
Andreas David Runheim
NPI 1811948136
$39,237.04
in general payments reported to CMS, 2019-2025
91 companies · $6,802 in 2025
The $6,802 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,585 · 2020: $4,336 · 2021: $4,720 · 2022: $5,083 · 2023: $6,323 · 2024: $7,388 · 2025: $6,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Consulting Fee: $1,188 · Travel and Lodging: $985 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,155.17 |
| Consulting Fee | $1,188.00 |
| Travel and Lodging | $984.86 |
| Education | $185.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,487.23 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $2,486.25 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Biogen, INC. | $2,340.49 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Argenx US, INC. | $2,166.62 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Supernus Pharmaceuticals, INC. | $2,154.50 | 2019-2022 | |
| Ucb, INC. | $1,901.86 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Sunovion Pharmaceuticals INC. | $1,851.74 | 2019-2022 | |
| Medtronic, INC. | $1,689.81 | 2023-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Emd Serono, INC. | $1,626.64 | 2019-2025 | Mavenclad |
| Pfizer INC. | $1,556.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,031.04 | 2019-2024 | |
| Allergan, INC. | $1,021.82 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $934.87 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $895.29 | 2020-2025 | |
| Eisai INC. | $836.52 | 2019-2025 |
Show all 91 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Runheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.